References

1. Drossman DA (2006) The functional gastrointestinal disorders and the Rome III process. Gastroenterology 130: 1377-1390. View
2. Lovell RM, Ford AC (2012) Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 10: 712-721. e4. View
3. Gwee KA, Lu CL, Ghoshal UC (2009) Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed. J Gastroenterol Hepatol 24: 1601-1607. View
4. Han SH, Lee OY, Bae SC, Lee SH, Chang YK, et al. (2006) Prevalence of irritable bowel syndrome in Korea: population-based survey using the Rome II criteria. J Gastroenterol Hepatol 21: 1687-1692. View
5. Guilera M, Balboa A, Mearin F (2005) Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol 100: 1174-1184. View
6. Drossman DA, Morris CB, Schneck S, Hu YJ, Norton NJ, et al. (2009) International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol 43: 541-550. View
7. Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT (2013) A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manag Care Pharm 19: 755-764. View
8. Harris LA, Hansel S, DiBaise J, Crowell MD (2006) Irritable bowel syndrome and chronic constipation: emerging drugs, devices, and surgical treatments. Curr Gastroenterol Rep 8: 282-290. View
9. Sanchez MI, Bercik P Epidemiology and burden of chronic constipation. (2011) Can J Gastroenterol 25 Suppl B: 11B-15B. View
10. Rao SS, Go JT (2010) Update on the management of constipation in the elderly: new treatment options. Clin Interv Aging 5: 163-171. View
11. Borum ML (2001) Constipation: evaluation and management. Prim Care 28: 577-590. View
12. Locke GR 3rd, Pemberton JH, Phillips SF (2000) American Gastroenterological Association Medical Position Statement: guidelines on constipation. Gastroenterology 119: 1761-1766. View
13. El-Serag HB, Talley NJ (2004) Systemic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 19: 643-654. View
14. Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW (1998) Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci 43: 2398- 2404. View
15. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, et al. (1999) Functional gastroduodenal disorders. Gut 45 Suppl 2: II37-42. View
16. Parkman HP, Hasler WL, Fisher RS; American Gastroenterological Association (2004) American Gastroenterological Association medical position statement: diagnosis and treatment of gastroparesis. Gastroenterology 127: 1589-1591. View
17. Deruyttere M, Lepoutre L, Heylen H, Samain H, Pennoit H (1987) Cisapride in the management of chronic functional dyspepsia: a multicenter, doubleblind, placebo-controlled study. Clin Ther 10: 44-51. View
18. Muller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, et al. (2001) Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 15: 1655-1666. View
19. Abell TL, Camilleri M, DiMagno EP, Hench VS, Zinsmeister AR, et al. (1991) Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci 36: 616-620. View
20. Camilleri M (2001) Review article: tegaserod. Aliment Pharmacol Ther 15: 277-289. View
21. Mohammad S, Zhou Z, Gong Q, January CT (1997) Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 273: H2534-2538. View
22. Hansen MB, Skadhauge E (1997) Signal transduction pathways for serotonin as an intestinal secretagogue. Comp Biochem Physiol A Physiol 118: 283-290. View
23. Grider JR, Foxx-Orenstein AE, Jin JG (1998) 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 115: 370-380. View
24. Jin JG, Foxx-Orenstein AE, Grider JR (1999) Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J Pharmacol Exp Ther 288: 93-97. View
25. Baker DE (2005) Rationale for using serotonergic agents to treat irritable bowel syndrome. Am J Health Syst Pharm 62: 700-711; quiz 712-703. View
26. Kim DY, Camilleri M (2000) Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 95: 2698-2709. View
27. Gershon MD, Wade PR, Kirchgessner AL, Tamir H (1990) 5-HT receptor subtypes outside the central nervous system. Roles in the physiology of the gut. Neuropsychopharmacology 3: 385-395. View
28. Furness JB, Costa M (1982) Neurons with 5-hydroxytryptamine-like immunoreactivity in the enteric nervous system: their projections in the guinea-pig small intestine. Neuroscience 7: 341-349. View
29. Galligan JJ, Surprenant A, Tonini M, North RA (1988) Differential localization of 5-HT1 receptors on myenteric and submucosal neurons. Am J Physiol 255: G603-611. View
30. Coulie B TJ, Janssens J (1997) Influence of buspirone-induced fundus relaxation: on the perception of gastric distention in man. Gastroenterology 112: A304.
31. Di Stefano M VR, Sifrim D, Tack J (2004) Effects of buspirone, a 5-HT1A receptor agonist, on oesophageal peristalsis and lower esophageal sphincter function in healthy volunteers. Gastroenterology 126: A638. View
32. Coulie B, Tack J, Maes B, Geypens B, De Roo M, et al. (1997) Sumatriptan, a selective 5-HT1 receptor agonist, induces a lag phase for gastric emptying of liquids in humans. Am J Physiol 272: G902-908. View
33. Coulie B, Tack J, Maes B, Geypens B, De Roo M, et al. (1997) Sumatriptan, a selective 5-HT1 receptor agonist, induces a lag phase for gastric emptying of liquids in humans. Am J Physiol 272: G902-908. View
34. Kuemmerle JF, Murthy KS, Grider JR, Martin DC, Makhlouf GM (1995) Coexpression of 5-HT2A and 5-HT4 receptors coupled to distinct signaling pathways in human intestinal muscle cells. Gastroenterology 109: 1791- 1800. View
35. Borman RA, Tilford NS, Harmer DW, Day N, Ellis ES, et al. (2002) 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Br J Pharmacol 135: 1144-1151. View
36. Launay JM, Schneider B, Loric S, Da Prada M, Kellermann O (2006) Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells. Faseb J 20: 1843-1854. View
37. Roth BL (2007) Drugs and valvular heart disease. N Engl J Med 356: 6-9. View
38. Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, et al. (2008) 5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol 60: 253- 262. View
39. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, et al. (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337: 581-588. View
40. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, et al. (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102: 2836-2841. View
41. Derkach V, Surprenant A, North RA (1989) 5-HT3 receptors are membrane ion channels. Nature 339: 706-709. View
42. Moss HE, Sanger GJ (1990) The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension. Br J Pharmacol 100: 497-501. View
43. von der Ohe MR, Camilleri M, Kvols LK (1994) A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. Gastroenterology 106: 1184-1189. View
44. Pan H, Galligan JJ (1994) 5-HT1A and 5-HT4 receptors mediate inhibition and facilitation of fast synaptic transmission in enteric neurons. Am J Physiol 266: G230-238. View
45. Gershon MD, Tack J (2007) The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132: 397-414. View
46. Reeves JJ, Bunce KT, Humphrey PP (1991) Investigation into the 5-hydroxytryptamine receptor mediating smooth muscle relaxation in the rat oesophagus. Br J Pharmacol 103: 1067-1072. View
47. Prins NH, Akkermans LM, Lefebvre RA, Schuurkes JA (2000) 5-HT(4) receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle. Br J Pharmacol 131: 927-932. View
48. Lee JW, Sung KW, Lee OY, Lee SE, Sohn CI (2012) The effects of 5-HT4 receptor agonist, mosapride citrate, on visceral hypersensitivity in a rat model. Dig Dis Sci 57: 1517-1524. View
49. Sengupta JN, Mickle A, Kannampalli P, Spruell R, McRorie J, et al. (2014) Visceral analgesic effect of 5-HT(4) receptor agonist in rats involves the rostroventral medulla (RVM). Neuropharmacology 79: 345-358. View
50. Hoffman JM, Tyler K, MacEachern SJ, Balemba OB, Johnson AC, et al.(2012) Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology 142: 844-854 e844. View
51. Conductier G, Dusticier N, Lucas G, Cote F, Debonnel G, et al. (2006) Adaptive changes in serotonin neurons of the raphe nuclei in 5-HT(4) receptor knock-out mouse. Eur J Neurosci 24: 1053-1062. View
52. Bockaert J, Claeysen S, Compan V, Dumuis (2011) A 5-HT(4) receptors, a place in the sun: act two. Curr Opin Pharmacol 11: 87-93. View
53. Hancox JC, McPate MJ, El Harchi A, Zhang YH (2008) The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 119: 118-132. View
54. Walker BD, Singleton CB, Bursill JA, Wyse KR, Valenzuela SM, et al. (1999) Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. Br J Pharmacol 128: 444-450. View
55. Meyers NL TJ, Middleton S et al. (2002) Efficacy and safety of renzapride in patients with constipation-predominant irritable bowel syndrome. Gut 51: A10.
56. Meyers NL, Hickling RI (2008) Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D 9: 37-63. View
57. Bowersox SS, Lightning LK, Rao S, Palme M, Ellis D, et al. (2011) Metabolism and pharmacokinetics of naronapride (ATI-7505), a serotonin 5-HT(4) receptor agonist for gastrointestinal motility disorders. Drug Metab Dispos 39: 1170-1180. View
58. Tack J, Camilleri M, Chang L, Chey WD, Galligan JJ, et al. (2012) Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 35: 745-767. View
59. Lee MJ, Cho KH, Park HM, Sung HJ, Choi S, et al.(2014) Pharmacological profile of DA-6886, a novel 5-HT4 receptor agonist to accelerate colonic motor activity in mice. Eur J Pharmacol 735: 115-122. View
60. De Maeyer JH, Lefebvre RA, Schuurkes JA (2008) 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 20: 99-112. View
61. Wagstaff AJ, Frampton JE, Croom KF (2003) Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women. Drugs 63: 1101-1120. View
62. Appel-Dingemanse S (2002) Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. Clin Pharmacokinet 41: 1021-1042. View
63. Shire-Movetis (2009) Resolor (prucalopride) Summary of product characteristics.
64. Beattie DT, Higgins DL, Ero MP, Amagasu SM, Vickery RG, et al. (2013) An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954. Vascul Pharmacol 58: 150- 156. View
65. Manini ML, Camilleri M, Goldberg M, Sweetser S, McKinzie S, et al. (2010) Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 22: 42-49, e47-48. View
66. Nguyen A, Camilleri M, Kost LJ, Metzger A, Sarr MG, et al. (1997) SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J Pharmacol Exp Ther 280: 1270-1276. View
67. Greenwood-Van Meerveld B, Venkova K, Hicks G, Dennis E, Crowell MD (2006) Activation of peripheral 5-HT receptors attenuates colonic sensitivity to intraluminal distension. Neurogastroenterol Motil 18: 76-86. View
68. Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, et al. (2003) An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 52: 671-676. View
69. Novick J, Miner P, Krause R, Glebas K, Bliesath H, et al. (2002) A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 16: 1877-1888. View
70. Kim YS, Choi SC, Park JM, Choi CH, Lee DH, et al. (2010) The effect of tegaserod on symptoms and quality of life in korean women with irritable bowel syndrome with constipation. J Neurogastroenterol Motil 16: 61-70. View
71. Johanson JF, Wald A, Tougas G, Chey WD, Novick JS, et al. (2004) Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2: 796-805. View
72. Kamm MA, Muller-Lissner S, Talley NJ, Tack J, Boeckxstaens G, et al. (2005) Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 100: 362-372. View
73. Ferrau O, Pustorino S, Luzza G, Turiano S, Familiari L, et al. (1980) [Comparative study of the effects of bromopride and metoclopramide on gastric emptying in humans]. Clin Ter 93: 33-38. View
74. Sabbatini F, Minieri M, Manzi G, Piai G, D'Angelo V, et al. (1991) Clinical efficacy and safety of cisapride and clebopride in the management of chronic functional dyspepsia: a double-blind, randomized study. Ital J Gastroenterol 23: 1-4. View
75. Kim HS, Choi EJ, Park H (2008) The effect of mosapride citrate on proximal and distal colonic motor function in the guinea-pig in vitro. Neurogastroenterol Motil 20: 169-176. View
76. Kadowaki M, Wang XO, Shimatani H, Yoneda S, Takaki M (2002) 5-HT4 receptor enhances the propulsive power of the peristaltic reflex in the rat distal colon. Auton Neurosci 99: 62-65. View
77. Shimatani H, Kojima Y, Kadowaki M, Nakagawa T, Fujii H, et al. (2003) A 5-HT4 agonist mosapride enhances rectorectal and rectoanal reflexes in guinea pigs. Am J Physiol Gastrointest Liver Physiol 285: G389-395. View
78. Kojima Y, Nakagawa T, Katsui R, Fujii H, Nakajima Y, et al. (2005) A 5-HT4 agonist, mosapride, enhances intrinsic rectorectal and rectoanal reflexes after removal of extrinsic nerves in guinea pigs. Am J Physiol Gastrointest Liver Physiol 289: G351-360. View
79. Takaki M, Goto K, Kawahara I (2014) The 5-hydroxytryptamine 4 Receptor Agonist-induced Actions and Enteric Neurogenesis in the Gut. J Neurogastroenterol Motil 20: 17-30. View
80. Bang CS, Kim JH, Baik GH, Kim HS, Park SH, et al. (2014) Mosapride treatment for functional dyspepsia: A meta-analysis. J Gastroenterol Hepatol. View
81. Hallerback BI, Bommelaer G, Bredberg E, Campbell M, Hellblom M, et al. (2002) Dose finding study of mosapride in functional dyspepsia: a placebocontrolled, randomized study. Aliment Pharmacol Ther 16: 959-967. View
82. Shin A, Camilleri M, Kolar G, Erwin P, West CP, et al. (2014) Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 39: 239-253. View
83. Briejer MR, Bosmans JP, Van Daele P, Jurzak M, Heylen L, et al. (2001) The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol 423: 71-83. View
84. Briejer MR, Prins NH, Schuurkes JA (2001) Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil 13: 465-472. View
85. Camilleri M, Kerstens R, Rykx A, Vandeplassche L (2008) A placebocontrolled trial of prucalopride for severe chronic constipation. N Engl J Med 358: 2344-2354. View
86. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L (2009) Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 58: 357-365. View
87. Quigley EM, Vandeplassche L, Kerstens R, Ausma J (2009) Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 29: 315-328. View
88. Yiannakou Y BM, Schiefke I, Piessevaux H, Filip R, Stephenson D, Green A, Levine A (2014) Efficacy and safety of prucalopride in men with chronic constipation: a phase 3, randomized, double-blind, placebo-controlled trial. Gastroenterology 146: S160.
89. Beattie DT, Armstrong SR, Shaw JP, Marquess D, Sandlund C, et al. (2008) The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 378: 139-147. View
90. Goldberg M, Li YP, Johanson JF, Mangel AW, Kitt M, et al. (2010) Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther 32: 1102-1112. View
91. Palme M MP, Ellis DJ, Marmon T, Canafax DM (2010) 905 A Novel Gastrointestinal Prokinetic, ATI-7505, Increased Spontaneous Bowel Movements (Sbms) in a Phase II, Randomized, Placebo-Controlled Study of Patients With Chronic Idiopathic Constipation (CIC). Gastroenterology 138: S128-129. View
92. SK Chemicals Co., Ltd. (2013) A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation. View
93. SK Chemicals Co., Ltd. (2014) Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation. View
94. Shin A AA, Boldingh A, Burton DD, Ryks M, Rhoten DL, Zinsmeister AR, Camilleri M (2014) Effects of YKP10811, a Selective 5-HT4 Receptor Agonist, in Patients with Functional Constipation: A Randomized, Controlled, Phase II Study. Gastroenterology 146: S902-903. View
95. Dong-A Pharmaceutical Co., Ltd. (2012) Phase I Clinical Trial of DA-6886 in Healthy Male Subjects. View
96. Moon JH, Lee MJ, Cho KH, Im W, Choi SH (2014) Effects of DA-6886 on Colonic Motility in Conscious Guinea Pigs. Gastroenterology 146: S357- 358.
97. Beattie DT, Armstrong SR, Vickery RG, Tsuruda PR, Campbell CB, et al. (2011) The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol 2: 25. View
98. Theravance, Inc. (2012) A Phase 1, Multiple Intravenous Dose Study to Examine the Safety, Tolerability, and Pharmacokinetics of Intravenous TD- 8954, a 5-HT4 Receptor Agonist, in Healthy Subjects. View
99. Available from: http://www.fda.gov/newsevents/newsroom/ pressannouncements/ucm149533.htm View
100. Shaklai M, Pinkhas J, de Vries A (1974) Metoclopramide and cardiac arrhythmia. Br Med J 2: 385. View
101. Available from: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyi nformationforpatientsandproviders/ucm103223.htm View
102. Villalon CM, Centurion D (2007) Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/ mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol 376: 45-63. View
103. Tougas G, Snape WJ, Jr., Otten MH, Earnest DL, Langaker KE, et al. (2002) Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 16: 1701-1708. View
104. Quigley EM, Wald A, Fidelholtz J, Boivin M, Pecher E, et al. (2006) Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies. Clin Gastroenterol Hepatol 4: 605-613. View
105. Fried M, Beglinger C, Bobalj NG, Minor N, Coello N, et al. (2005) Tegaserod is safe, well tolerated and effective in the treatment of patients with nondiarrhoea irritable bowel syndrome. Eur J Gastroenterol Hepatol 17: 421- 427. View
106. Potet F, Bouyssou T, Escande D, Baro I (2001) Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther 299: 1007-1012. View
107. Smith JA, Beattie DT, Marquess D, Shaw JP, Vickery RG, et al. (2008) The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 378: 125-137. View